Mizuho Medy Co.,Ltd. (TYO:4595)

Market Cap	34.44B +24.8%
Revenue (ttm)	9.67B -12.0%
Net Income	2.81B -19.6%
EPS	147.57 -29.7%
Shares Out	19.05M
PE Ratio	12.25
Forward PE	n/a
Dividend	100.00 (5.58%)
Ex-Dividend Date	Dec 29, 2025

Volume	232,000
Average Volume	67,360
Open	1,809.00
Previous Close	1,808.00
Day's Range	1,754.00 - 1,813.00
52-Week Range	1,341.00 - 1,827.00
Beta	0.50
RSI	54.47
Earnings Date	Feb 13, 2026

About Mizuho Medy

Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid amplification test products comprising gene analysis instruments and mycoplasma pneumoniae nucleic acid kits. It also provides rapid immunoassay products, including influenza virus antigen test kit; RS virus and human metapneumovirus antigen test kit; streptococcus pneumoniae antigen and legio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1977
• Employees: 187
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4595

Financial Performance

In 2024, Mizuho Medy's revenue was 11.43 billion, an increase of 4.00% compared to the previous year's 10.99 billion. Earnings were 3.77 billion, a decrease of -0.03%.